A Mechanistic Proof-of-concept Clinical Trial With JX-594, a Targeted Multi-mechanistic Oncolytic Poxvirus, in Patients With Metastatic Melanoma
A Mechanistic Proof-of-concept Clinical Trial With JX-594, a Targeted Multi-mechanistic Oncolytic Poxvirus, in Patients With Metastatic Melanoma
复制标题
DOI：
10.1038/mt.2011.132
复制
发表时间：
2011-10-01
影响因子：
12.4
通讯作者：
Kirn, David H.
中科院分区：
文献类型：
--
作者：
Hwang, Tae-Ho;Moon, Anne;Kirn, David H.
JX-594是一种靶向和表达粒细胞巨噬细胞集落刺激因子（GM-CSF）的溶瘤痘病毒，旨在通过病毒溶瘤和肿瘤特异性免疫选择性地在癌细胞中复制和破坏癌细胞。为了研究JX-594在人体中的作用机制（MOA），以相当于
JX-594 is a targeted and granulocyte macrophage-colony stimulating factor (GM-CSF)-expressing oncolytic poxvirus designed to selectively replicate in and destroy cancer cells through viral oncolysis and tumor-specific immunity. In order to study the mechanisms-of-action (MOA) of JX-594 in humans, a mechanistic proof-of-concept clinical trial was performed at a low dose equivalent to